Search

Your search keyword '"Manara, Maria Cristina"' showing total 375 results

Search Constraints

Start Over You searched for: Author "Manara, Maria Cristina" Remove constraint Author: "Manara, Maria Cristina"
375 results on '"Manara, Maria Cristina"'

Search Results

2. Correction: Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells

3. Supplementary Figure 5 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

4. Supplementary Figure 3 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

5. Data from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

6. Supplementary video 1 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

7. Supplementary Figure 9 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

8. Supplementary Figure 11 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

9. Supplementary Figure 4 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

10. Supplementary Figure 2 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

11. Supplementary Table S1 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

12. Supplementary video 2 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

13. Supplementary Figure 7 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

14. Supplementary Figure 6 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

15. Supplementary Figure 8 from Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

18. IL-1 Family Members in Bone Sarcomas

19. Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

24. Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells

27. Data from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy

28. Figure S1 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy

29. Supplementary Materials and Methods from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy

30. Table S2 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy

31. Supplementary Figure S5 from Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents

32. Fig.s3new from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors

33. Table S1 from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors

34. Table S2-S3-S4 from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors

35. Data from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors

36. Fig.S5 new from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors

37. Supplementary Methods from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin

38. Supplementary Figure 5 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin

39. Supplementary Figure 4 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin

40. Supplementary Figure 1 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin

41. SupplementarydataREV from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors

42. Supplementary Figure 2 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin

43. Data from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma

44. Supplementary Table 1 from Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents

45. Supplementary Figure 3 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin

46. Supplementary Tables 1-6 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin

47. Supplementary Data from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma

48. Supplementary Figure 6 from CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin

49. Supplementary Figure 1 from Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling

50. Supplementary Figure 2 from Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling

Catalog

Books, media, physical & digital resources